GEXVal to present AI Drug Discovery Platform RePhaIND® at BioJapan Seminar

GEXVal Inc.
September 25, 2026

GEXVal Inc. to Present at BioJapan 2026 Seminar “From Analytical AI to Exploratory AI:
The RePhaIND^® Paradigm Shift in Drug Discovery”

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that it will host a panel discussion at BioJapan 2026.
AI-driven drug discovery has attracted growing interest worldwide in recent years, spanning the full spectrum from research and development to commercialization. We have been advancing drug repurposing through our proprietary drug discovery platform, RePhaIND^{® 1)}. This technology platform can also be applied to the exploration of novel drug targets, and we intend to use it to open up new possibilities in drug discovery beyond drug repurposing.
In this seminar, we will present the evolution from "AI that analyzes" to "AI that explores," made possible by combining RePhaIND^® with AI agents. We will draw on technical insights from our work with the Graph Attention Autoencoder (GATE) ²⁾, as well as the practical experience we have gained in applying these technologies.
GEXVal will also be exhibiting in Hall D during BioJapan 2026.
For additional details, please see our news release.

**Presentation Details**

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaching the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

1) About RePhaIND^®：Revolutionary Pharmacoinformatics to Find IND (Investigational New Drug)
RePhaIND^® is GEXVal's proprietary AI-driven drug discovery platform with three key features:
EMPOWER: Discover hidden relationships between drug candidates and diseases
ACCELERATE: Dramatically improve efficiency compared to conventional methods
REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process
RePhaIND^® is a registered trademark of GEXVal Inc. in Japan, China, Hong Kong, Korea, Australia, Europe, UK, and US and a trademark in other countries and regions.

2) About Graph Attention Autoencoder（GATE）
Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com